Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$110B
P/E
30
Revenue Growth
+12.0%
Gross Margin
N/A
ROE
N/A
About Vertex Pharmaceuticals
Listed on the NASDAQ, Vertex Pharmaceuticals operates as a large-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. Dominant cystic fibrosis franchise with expanding pain and gene therapy pipeline. Valued at 30x trailing earnings with a $110B market capitalization, the business is characterized by consistent top-line gains, reporting +12% revenue change year-over-year.
Expert Coverage
Unlock Full VRTX Analysis
Expert analysis and coverage for Vertex Pharmaceuticals
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-06-22
More in Biotech & Genomics
BEAM
Beam Therapeutics
90
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%RXRX
Recursion Pharmaceuticals
88
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%